Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Michael Kleerekoper (August 18, 1944 to May 10, 2018): In Relentless Pursuit of a Better Way.

Kleerekoper M.

J Bone Miner Res. 2018 Sep;33(9):1553-1555. doi: 10.1002/jbmr.3548. Epub 2018 Aug 1. No abstract available.

2.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016.

Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB.

Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42. doi: 10.4158/EP161435.GL.

PMID:
27662240
3.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY.

Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB.

Endocr Pract. 2016 Sep;22(9):1111-8. doi: 10.4158/EP161435.ESGL. Erratum in: Endocr Pract. 2017 Mar;23 (3):383.

PMID:
27643923
4.

Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.

Kleerekoper M, Greenspan SL, Lewiecki EM, Miller PD, Kendler DL, Maricic M, Keaveny TM, Kopperdahl DL, Ruff VA, Wan X, Janos B, Krohn K.

J Bone Joint Surg Am. 2014 Jun 4;96(11):e90. Epub 2014 Jun 4.

PMID:
24897747
5.

Secondary osteoporosis: endocrine and metabolic causes of bone mass deterioration.

Miazgowski T, Kleerekoper M, Felsenberg D, Stěpán JJ, Szulc P.

J Osteoporos. 2012;2012:907214. doi: 10.1155/2012/907214. Epub 2012 Feb 23. No abstract available.

6.

Evaluation of trabecular microarchitecture in nonosteoporotic postmenopausal women with and without fracture.

Kijowski R, Tuite M, Kruger D, Munoz Del Rio A, Kleerekoper M, Binkley N.

J Bone Miner Res. 2012 Jul;27(7):1494-500. doi: 10.1002/jbmr.1595.

7.

Clinical applications for vitamin D assays: what is known and what is wished for.

Kleerekoper M, Schleicher RL, Eisman J, Bouillon R, Singh RJ, Holick MF.

Clin Chem. 2011 Sep;57(9):1227-32. doi: 10.1373/clinchem.2010.154997. Epub 2011 Apr 18. No abstract available.

8.

Poststroke fractures in a bi-ethnic community.

Lisabeth LD, Morgenstern LB, Wing JJ, Sanchez BN, Zahuranec DB, Skolarus LE, Burke JF, Kleerekoper M, Smith MA, Brown DL.

J Stroke Cerebrovasc Dis. 2012 Aug;21(6):471-7. doi: 10.1016/j.jstrokecerebrovasdis.2010.11.009. Epub 2011 Feb 21.

9.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM; AACE Osteoporosis Task Force.

Endocr Pract. 2010 Nov-Dec;16 Suppl 3:1-37. No abstract available.

10.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM.

Endocr Pract. 2010 Nov-Dec;16(6):1016-9. No abstract available.

11.

Reduced bone mineral density is not associated with significantly reduced bone quality in men and women practicing long-term calorie restriction with adequate nutrition.

Villareal DT, Kotyk JJ, Armamento-Villareal RC, Kenguva V, Seaman P, Shahar A, Wald MJ, Kleerekoper M, Fontana L.

Aging Cell. 2011 Feb;10(1):96-102. doi: 10.1111/j.1474-9726.2010.00643.x. Epub 2010 Nov 15.

12.

Postmenopausal hormone therapy: an Endocrine Society scientific statement.

Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH; Endocrine Society.

J Clin Endocrinol Metab. 2010 Jul;95(7 Suppl 1):s1-s66. doi: 10.1210/jc.2009-2509. Epub 2010 Jun 21. Review.

13.

New and improved FRAX® for predicting fragility fractures: a work in progress.

Kleerekoper M.

Expert Rev Endocrinol Metab. 2010 Mar;5(2):165-167. doi: 10.1586/eem.10.8. No abstract available.

PMID:
30764040
14.

Changes in trabecular microarchitecture in postmenopausal women on bisphosphonate therapy.

Greenspan SL, Perera S, Recker R, Wagner JM, Greeley P, Gomberg BR, Seaman P, Kleerekoper M.

Bone. 2010 Apr;46(4):1006-10. doi: 10.1016/j.bone.2009.12.025. Epub 2010 Jan 4.

15.

An unsatisfactory report card.

Kleerekoper M.

Acta Neurol Scand. 2009 Nov;120(5):368-9. doi: 10.1111/j.1600-0404.2009.01225.x. No abstract available.

16.

Fat embolism syndrome.

Stein PD, Yaekoub AY, Matta F, Kleerekoper M.

Am J Med Sci. 2008 Dec;336(6):472-7. doi: 10.1097/MAJ.0b013e318172f5d2.

PMID:
19092320
17.

Osteoporosis prevention and management: an evidence-based review.

Kleerekoper M, Gold DT.

Clin Obstet Gynecol. 2008 Sep;51(3):556-63. doi: 10.1097/GRF.0b013e3181809ae0. Review.

PMID:
18677150
18.

Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease.

Raggi P, Kleerekoper M.

Clin J Am Soc Nephrol. 2008 May;3(3):836-43. doi: 10.2215/CJN.02910707. Epub 2008 Mar 5. Review.

19.

Soy isoflavones in the management of postmenopausal osteoporosis.

Atmaca A, Kleerekoper M, Bayraktar M, Kucuk O.

Menopause. 2008 Jul-Aug;15(4 Pt 1):748-57. doi: 10.1097/gme.0b013e31815c1e7f. Review.

PMID:
18277912
20.

Risk of fractures after stroke.

Brown DL, Morgenstern LB, Majersik JJ, Kleerekoper M, Lisabeth LD.

Cerebrovasc Dis. 2008;25(1-2):95-9. Epub 2007 Dec 6.

PMID:
18057878
21.

Agonist activity of the 3-hydroxy metabolites of tibolone through the oestrogen receptor in the mouse N20.1 oligodendrocyte cell line and normal human astrocytes.

Guzmán CB, Zhao C, Deighton-Collins S, Kleerekoper M, Benjamins JA, Skafar DF.

J Neuroendocrinol. 2007 Dec;19(12):958-65.

PMID:
18001325
22.

Glucocorticoid-induced osteoporosis.

Berris KK, Repp AL, Kleerekoper M.

Curr Opin Endocrinol Diabetes Obes. 2007 Dec;14(6):446-50. Review.

PMID:
17982350
23.

Postmenopausal osteoporosis: an update on current and future therapeutic options.

Camacho PM, Armamento-Villareal R, Kleerekoper M.

Expert Rev Endocrinol Metab. 2007 Jan;2(1):79-90. doi: 10.1586/17446651.2.1.79.

PMID:
30743750
24.

How common are functional incidentalomas of the parathyroid gland?

Koenig K, Kleerekoper M.

Nat Clin Pract Endocrinol Metab. 2006 Jun;2(6):316-7. No abstract available.

PMID:
16932308
25.

Differential associations for menopause and age in measures of vitamin K, osteocalcin, and bone density: a cross-sectional exploratory study in healthy volunteers.

Lukacs JL, Booth S, Kleerekoper M, Ansbacher R, Rock CL, Reame NE.

Menopause. 2006 Sep-Oct;13(5):799-808.

PMID:
16912661
26.

Osteoporosis prevention and therapy: preserving and building strength through bone quality.

Kleerekoper M.

Osteoporos Int. 2006 Dec;17(12):1707-15. Epub 2006 Aug 15. Review.

PMID:
16909196
27.

Secondary osteoporosis: a review of the recent evidence.

Painter SE, Kleerekoper M, Camacho PM.

Endocr Pract. 2006 Jul-Aug;12(4):436-45. Review.

PMID:
16901802
28.

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause.

Cobin RH, Futterweit W, Ginzburg SB, Goodman NF, Kleerekoper M, Licata AA, Meikle AW, Petak SM, Porte KL, Sellin RV, Smith KD, Verso MA, Watts NB; AACE Menopause Guidelines Revision Task Force.

Endocr Pract. 2006 May-Jun;12(3):315-37. No abstract available. Erratum in: Endocr Pract. 2008 Sep;14(6):802-3. multiple author names added.

PMID:
16772207
29.

Is BMD testing appropriate for all menopausal women?

Kleerekoper M, Nelson DA.

Int J Fertil Womens Med. 2005 Mar-Apr;50(2):61-6. Review.

PMID:
16334412
30.

Monitoring osteoporosis therapy.

Kleerekoper M, Camacho P.

Clin Chem. 2005 Dec;51(12):2227-8. No abstract available.

31.

Activity of estradiol and selective estrogen receptor modulators in the mouse N20.1 oligodendrocyte/astrocytes cell line.

Guzmán CB, Deighton-Collins S, Martinez A, Kleerekoper M, Zhao C, Benjamins JA, Skafar DF.

Neuro Endocrinol Lett. 2005 Oct;26(5):526-32.

PMID:
16264406
32.

Usefulness of bone mineral density to predict significant coronary artery disease.

Marcovitz PA, Tran HH, Franklin BA, O'Neill WW, Yerkey M, Boura J, Kleerekoper M, Dickinson CZ.

Am J Cardiol. 2005 Oct 15;96(8):1059-63. Epub 2005 Aug 22.

PMID:
16214438
33.

Prevention and treatment of postmenopausal osteoporosis.

Mahakala A, Thoutreddy S, Kleerekoper M.

Treat Endocrinol. 2003;2(5):331-45. Review.

PMID:
15981950
34.

Prevention of postmenopausal bone loss and treatment of osteoporosis.

Kleerekoper M.

Semin Reprod Med. 2005 May;23(2):141-8. Review.

PMID:
15852199
35.

Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.

Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH.

Osteoporos Int. 2005 Apr;16(4):372-9. Epub 2005 Jan 15.

PMID:
15654581
36.

The further evolution of hyperparathyroidism: Implications for clinical care.

Kleerekoper M.

Am J Med. 2004 Dec 1;117(11):884-6. No abstract available.

PMID:
15589499
37.

Neurologic disease, falls and fractures.

Fletcher D, Kleerekoper M.

J Neurol Sci. 2004 Aug 30;223(2):101-2. No abstract available.

PMID:
15337608
38.

Prevalence of osteoporosis in women referred for bone density testing: utility of multiple skeletal sites.

Nelson DA, Molloy R, Kleerekoper M.

J Clin Densitom. 1998 Spring;1(1):5-11.

PMID:
15304907
39.

The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements?

Miller PD, Bonnick SL, Johnston CC, Kleerekoper M, Lindsay RL, Sherwood LM, Siris ES.

J Clin Densitom. 1998 Fall;1(3):211-7.

PMID:
15304891
40.

Body composition profiles derived from dual-energy X-ray absorptiometry, total body scan, and mortality.

Krakauer JC, Franklin B, Kleerekoper M, Karlsson M, Levine JA.

Prev Cardiol. 2004 Summer;7(3):109-15.

41.

Treatment of osteoporosis.

Kleerekoper M.

Clin Obstet Gynecol. 2004 Jun;47(2):413-23. Review. No abstract available.

PMID:
15166867
42.

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.

Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR; AACE Osteoporosis Task Force.

Endocr Pract. 2003 Nov-Dec;9(6):544-64. No abstract available. Erratum in: Endocr Pract. 2004 Jan-Feb;10(1):90. Endocr Pract. multiple author names added.

PMID:
14715483
43.

Routine bone densitometry in elderly men?

Kleerekoper M.

Postgrad Med. 2002 Dec;112(6):62. No abstract available.

PMID:
12510447
44.

Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.

Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA.

J Clin Endocrinol Metab. 2002 Dec;87(12):5353-61. Review. No abstract available.

PMID:
12466320
45.

A woman attempting to discontinue hormone therapy.

Kleerekoper M.

JAMA. 2002 Nov 13;288(18):2264; author reply 2264-5. No abstract available.

PMID:
12425697
46.

Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.

Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA Jr.

J Bone Miner Res. 2002 Nov;17 Suppl 2:N2-11. Review. No abstract available.

PMID:
12412771
47.

Lessons from the skeleton: was the Women's Health Initiative (WHI) a primary prevention trial?

Kleerekoper M.

Osteoporos Int. 2002 Sep;13(9):685-7. No abstract available.

PMID:
12195531
48.

Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.

Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH.

JAMA. 2002 May 22-29;287(20):2668-76.

PMID:
12020302
49.

Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline.

Vesper HW, Demers LM, Eastell R, Garnero P, Kleerekoper M, Robins SP, Srivastava AK, Warnick GR, Watts NB, Myers GL.

Clin Chem. 2002 Feb;48(2):220-35. Review.

50.

How reliable are bone densitometry results?

Kleerekoper M.

Postgrad Med. 2001 Dec;110(6):51. No abstract available.

PMID:
11787408

Supplemental Content

Loading ...
Support Center